The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Exjade Dispersible

Novartis Europharm LimitedEU/1/06/356/001-009

Main Information

Trade NameExjade Dispersible
Active SubstancesDeferasirox
Dosage FormDispersible tablet
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/06/356/001-009

Group Information

ATC CodeV03AC Iron chelating agents
V03AC03 deferasirox


License statusAuthorised
Licence Issued28/08/2006
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back